Innovation Pharmaceuticals Inc (IPIX)

[sox040713]

That’s your speculation. It could also mean Leo didn’t receive the interim data from the CRO.

Let’s say he did receive the data. I’m not sure how much you can tell from an imcomplete population at week 6. Phase 2a (200 mg arm) result shows ~10% >= 2-point IGA improvement at week 6.

The DMC could recommend IPIX to end the trial early due to futility. Base on Leo’s frugal track record, he would’ve done it.

He just said that interim data will not be released - that could mean that he actually saw the data and was not impressed with it and decided not to share.